- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02417272
Total Disc Replacement Versus Anterior Cervical Decompression and Fusion (CERVIDISC)
Comparison of 2 Surgical Approaches in the Treatment of Cervical Degenerative Disc Disease: Total Disc Replacement Versus Anterior Cervical Decompression and Fusion
Background : Cervical degenerative disc disease is frequent and the consequence of aging. Degeneration may lead to disc herniation. Surgery is indicated in the presence of root compression with cervicobrachial neuralgia and/or myelopathy.
Purpose: The main objective of the study is the comparison of efficacy between total disc replacement (TDR) and Anterior Cervical Decompression and Fusion (ACDF) as surgical treatment of symptomatic cervical degenerative disc disease in term of "Success" rate, defined as preservation of adjacent segments, 24 months after surgery.
In our knowledge, there are no published data about randomized clinical trials comparing these radiological parameters (worsening of degeneration signs on static cervical spine radiographs and worsening of disc degeneration signs on MRI) at levels adjacent to surgery, between these 2 surgical approaches in patients suffering from cervical degenerative disc disease.
Study Overview
Status
Conditions
Detailed Description
Surgical treatment of cervical degenerative disc disease usually consists in neural decompression followed by intervertebral space reconstruction.
ACDF consists in interbody fusion by replacing disc space with a cage packed with bone substitute, and inserted into the anterior portion of the interspace. Fusion is successful in approximately 95% of patients with good to excellent clinical results in most of them. Unfortunately, up to 25% of these patients will develop degenerative changes at adjacent levels after surgery.
TDR consists in total disc replacement with preserved segmental motion decreasing load on adjacent levels.
Worsening of radiological degeneration signs at adjacent levels seems to be an important long term prognostic factor for reoperation.
In this trial, included patients will be randomly assigned to undergo either TDR or ACDF Six visits are planned during the study: pre inclusion visit within 3 months before surgery, inclusion/randomisation the day before surgery, 3 follow up visits (45 days, 6, and 12 months after surgery) and an end of study visit 24 months after surgery (or at time of withdrawal if relevant).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bordeaux, France, 33076
- Chirurgie Orthopedique
-
Nice, France, 06000
- CHU Nice - Unité de Chirurgie Rachidienne
-
Paris, France, 75013
- Chirurgie Orthopedique
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 18-60 years
- suffering from cervical disc degenerative disease (whatever the grade, level and intervertebral disc height) needing one-level surgical treatment due to either invalidating cervicobrachial nevralgia despite 3-month optimal medical treatment or neurological symptoms, with motion of surgical level at least equal to 2° degrees, and non-degenerative adjacent discs.
- Being affiliated to health insurance
- Having signed an informed consent (later than the day of inclusion and before any examination required by research)
Exclusion Criteria:
- Previous cervical traumatism and/or cervical surgery.
- Cervical degeneration defined as a Grade 4 according to modified Mehren classification and/or a Grade 5 according to Miyazaki et al classification on T2 magnetic resonance imaging (MRI), at symptomatic level and/or its adjacent levels.
- Myelopathy.
- Cervical spine instability.
- Presence of at least one major contraindication to surgery and/or general anaesthesia (ie, non-controlled coagulopathy, active infection, or serious underlying disease, auto-immune affection).
- Presence of at least one contraindication to either TDR or ACDF procedure.
- Presence of at least one contraindication to either static/dynamic radiographs or Magnetic Resonance Imaging (MRI).
- Severe radiological osteoporosis.
- Bone metabolic disease.
- Active cancer at time of inclusion into the study.
- Chronic intake of corticosteroids or any other treatment susceptible to interfere with study conduct and/or assessment (ie, immunosuppressive drugs).
- Unlikely to comply with the requirements of the study and/or to complete the study for psychological, social, familial or geographical reasons.
- No contraception for women of childbearing age
- Pregnant or breastfeeding women
- Being under guardianship or legal supervision.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Total disc replacement (TDR)
Total disc replacement with preserved segmental motion decreasing load on adjacent levels.
|
|
Experimental: Anterior Cervical Decompression and Fusion (ACDF)
Interbody fusion by replacing disc space with a cage packed with bone substitute, and inserted into the anterior portion of the interspace.
|
Axelle®
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To compare efficacy of TDR and ACDF as surgical treatment of cervical degenerative disc disease in term of "success rate" defined as absence of radiological degenerative disease at adjacent levels
Time Frame: 24 months after surgery
|
24 months after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Between-group comparison of tolerance
Time Frame: 24 months after surgery
|
This measure is a composite with :
|
24 months after surgery
|
Between-group comparison of efficacy
Time Frame: 45 days, 6, 12 and 24 months after surgery
|
This measure is a composite with :
|
45 days, 6, 12 and 24 months after surgery
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Olivier GILLE, Prof, University Hospital Bordeaux, France
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHUBX 2010/40
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Degenerative Disc Disease
-
Medtronic Spinal and BiologicsCompletedDegenerative Cervical Disc DiseaseSaudi Arabia, Greece, Serbia, Hungary, Czech Republic, Kuwait, Poland, Slovakia
-
Assiut UniversityNot yet recruiting
-
DePuy InternationalTerminatedCervical Degenerative Disc DiseaseAustralia, Germany, Italy, Malaysia, Netherlands, Spain, United Kingdom
-
Assistance Publique - Hôpitaux de ParisTerminatedCervical Degenerative Disc Disease | Kyphosis | Lumbar Degenerative Disc DiseaseFrance
-
Synergy Spine SolutionsMCRARecruitingCervical Degenerative Disc DiseaseUnited States
-
Orthofix Inc.TerminatedCervical Degenerative Disc DiseaseUnited States
-
Synergy Spine SolutionsMCRANot yet recruitingCervical Degenerative Disc DiseaseUnited Kingdom
-
Medtronic Spinal and BiologicsCompletedCervical Degenerative Disc DiseaseUnited States
-
NuVasiveCompletedCervical Degenerative Disc DiseaseUnited States
-
Alphatec Spine, Inc.Terminated
Clinical Trials on Surgical treatment of cervical degenerative disc disease (CP ESP®)
-
NLT SpineUnknownDegenerative Disc DiseaseIsrael